5 completed, 5 unknown, 2 recruiting, 2 withdrawn. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 5, Unknown 5, Recruiting 2, Withdrawn 2, Active not recruiting 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Transarterial chemoembolization: new trials by email Literature Review of Transarterial chemoembolization trials Research Report on Transarterial chemoembolization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere NRT6003 Injection, cTACE - Unresectable Hepatocellular Carcinoma | Phase 3 | Active not recruiting | Chengdu New Radiomedicine Technology Co. LTD. | 108 | 2025-04-15 | 2026-06-09 |
| The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma Atezolizumab, Bevacizumab, TACE - Hepatocellular Carcinoma | Phase 3 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 434 | 2021-07-06 | 2025-01-07 |
| Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC Sorafenib, Transarterial chemoembolization - Hepatocellular Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 158 | 2019-09-15 | 2020-03-25 |
| Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma Stereotactic Body Radiation, Transarterial Chemoembolization - Hepatocellular Carcinoma | Phase 3 | Recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 128 | 2019-05-27 | 2025-03-11 |
| Adjuvant Radiotherapy Comparing TACE for Curative HCC Transarterial chemoembolization, Radiotherapy - Hepatocellular Carcinoma | Phase 3 | Unknown | Guangxi Medical University | 150 | 2019-05-01 | 2023-01-27 |
| Adjuvant Therapies for Patients With HCC and MVI TACE, Sorafenib, TACE plus sorafenib - Hepatocellular Carcinoma | Phase 3 | Unknown | Guangxi Medical University | 240 | 2019-02-01 | 2020-01-10 |
| Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria Lenvatinib, PD-1 antibody, TACE - Hepatocellular Carcinoma | Phase 3 | Withdrawn | Sun Yat-sen University | 2019-01-01 | 2019-05-02 | |
| HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B. Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, Folfox Protocol - HepatoCellular Carcinoma | Phase 3 | Completed | Sun Yat-sen University | 315 | 2016-10-01 | 2023-06-12 |
| HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC Hepatic arterial infusion chemotherapy, Transarterial chemoembolization, TACE regimen - Hepatocellular Carcinoma | Phase 3 | Completed | Sun Yat-sen University | 214 | 2016-08-01 | 2024-07-23 |
| Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent - Child-Pugh Class A, Child-Pugh Class B | Phase 3 | Terminated | Stanford University | 13 | 2016-02-27 | 2024-03-12 |
| Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma Transarterial chemoembolization (TACE), Radiofrequency ablation combined with TACE, Microwave ablation combined with TACE - Liver Cancer | Phase 3 | Unknown | Sherief Abd-Elsalam | 50 | 2015-01-01 | 2018-01-09 |
| Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma liver resection, transarterial chemoembolization, carboplatin - Hepatocellular Carcinoma | Phase 3 | Unknown | Sun Yat-sen University | 198 | 2014-03-01 | 2016-04-28 |
| Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC) Transarterial Chemoembolization, CyberKnife SBRT - Recurrent Hepatocellular Carcinoma | Phase 3 | Withdrawn | Accuray Incorporated | 2011-02-01 | 2012-02-20 | |
| Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer sunitinib malate, Placebo, transarterial chemoembolization - Liver Cancer | Phase 2 / Phase 3 | Completed | Federation Francophone de Cancerologie Digestive | 78 | 2010-07-01 | 2022-03-18 |
| Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma transarterial chemoembolization - Liver Cancer | Phase 3 | Completed | Guangdong Provincial People's Hospital | 162 | 2008-01-01 | 2014-01-17 |
| Comparison Study of Transarterial Chemoembolization and Percutaneous Ethanol Injection for Multiple, Small HCCs Transarterial chemoembolization, Percutaneous ethanol injection therapy - Hepatocellular Carcinoma | Phase 3 | Completed | Seoul National University Hospital | 22 | 2005-10-01 | 2013-12-04 |
Carcinoma, Hepatocellular (14) · Liver Neoplasms (4)
Sun Yat-sen University (5) · Guangxi Medical University (2) · Accuray Incorporated (1) · Chengdu New Radiomedicine Technology Co. LTD. (1) · Federation Francophone de Cancerologie Digestive (1) · Guangdong Provincial People's Hospital (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Seoul National University Hospital (1) · Sherief Abd-Elsalam (1) · Stanford University (1)
China (9) · France (2) · Japan (2) · United States (2) · Austria (1) · Canada (1) · Egypt (1) · Germany (1) · Italy (1) · South Korea (1) · Spain (1)
Ming Shi, MD (3) · Daniel Chang, MD (2) · Albert Koong, MD, PhD (1) · Elshazly Sheta, Professor (1) · Erqi Liu Pollom, MD (1) · Ferial El-kalla, Professor (1) · Gaojun Teng (1) · Ibrahim Amer, Consultant (1) · J H Yoon, Professor (1) · Jordi Bruix, Prof. Dr. (1) · Michael Lock, M.D. (1) · Mohamed Elgharib, Professor (1) · Mohamed Elhendawy, Consultant (1) · Mohamed Hebbar, MD (1)
PMID 32576496, PMID 34648352, PMID 38568599, PMID 40302359
P30CA124435 (1)